180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.
Company profile
Ticker
ATNF, ATNFW
Exchange
Website
CEO
Jim N. Woody
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
KBL MERGER CORP. IV
SEC CIK
Corporate docs
Subsidiaries
180 Life Corp. • Katexco Callco ULC • CannBioRex Callco ULC • 180 Therapeutics LP • Katexco Purchaseco ULC • CannBioRex Purchaseco ULC • Katexco Pharmaceuticals Corp. • CannBioRex Pharmaceuticals Corp. • CannBioRex Pharma Limited ...
ATNF stock data
Latest filings (excl ownership)
8-K
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
4 Dec 23
424B3
Prospectus supplement
30 Nov 23
424B3
Prospectus supplement
30 Nov 23
8-K
Entry into a Material Definitive Agreement
29 Nov 23
8-K
180 Life Sciences Announces Review of Strategic Alternatives
28 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Other Events
18 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Oct 23
8-K
Termination of a Material Definitive Agreement
28 Sep 23
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q2 2023
66.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 19 |
| Opened positions | 7 |
| Closed positions | 5 |
| Increased positions | 2 |
| Reduced positions | 3 |
| 13F shares | Current |
|---|---|
| Total value | 77.79 mm |
| Total shares | 4.93 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| KBL Iv Sponsor | 2.22 mm | $5.47 mm |
| Bauer Ronald | 1.41 mm | $7.02 mm |
| Bridgman Craig | 673.51 k | $3.36 mm |
| CNH Partners | 336.51 k | $3.77 mm |
| Renaissance Technologies | 120.00 k | $140.00 k |
| MSD Partners | 90.00 k | $1.06 mm |
| Two Sigma Securities | 22.81 k | $269.00 k |
| Vanguard | 15.38 k | $17.99 mm |
| BLK Blackrock | 14.65 k | $17.15 mm |
| Geode Capital Management | 10.60 k | $12.40 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Sep 23 | Marrone Pamela G | Common Stock | Grant | Acquire A | No | No | 0 | 22,388 | 0.00 | 34,857.019 |
| 4 Sep 23 | Marrone Pamela G | NQSO Common Stock | Grant | Acquire A | No | No | 0.67 | 15,000 | 10.05 k | 15,000 |
| 4 Sep 23 | Jr. Donald A. McGovern | Common Stock | Grant | Acquire A | No | No | 0 | 25,186 | 0.00 | 55,285 |
| 4 Sep 23 | Jr. Donald A. McGovern | NQSO Common Stock | Grant | Acquire A | No | No | 0.67 | 44,776 | 30.00 k | 44,776 |
| 4 Sep 23 | Jr. Donald A. McGovern | NQSO Common Stock | Grant | Acquire A | No | No | 0.67 | 15,000 | 10.05 k | 15,000 |
| 4 Sep 23 | Ozan Pamir | Stock Option Common Stock | Grant | Acquire A | No | No | 0.67 | 15,000 | 10.05 k | 15,000 |
| 4 Sep 23 | Lawrence Marshall Gold | Common Stock | Grant | Acquire A | No | No | 0 | 21,455 | 0.00 | 24,745 |
| 4 Sep 23 | Lawrence Marshall Gold | NQSO Common Stock | Grant | Acquire A | No | No | 0.67 | 15,000 | 10.05 k | 15,000 |
| 4 Sep 23 | Lawrence Steinman | NQSO Common Stock | Grant | Acquire A | No | No | 0.67 | 15,000 | 10.05 k | 15,000 |
News
Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
29 Nov 23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Nov 23
12 Health Care Stocks Moving In Tuesday's After-Market Session
28 Nov 23
12 Health Care Stocks Moving In Tuesday's After-Market Session
14 Nov 23
12 Health Care Stocks Moving In Monday's After-Market Session
13 Nov 23